Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: A phase I study

British Journal of Cancer

Volumn 79, Issue 5-6, 1999, Pages 984-990

  Ueoka, H ^a   Tabata, M ^a   Kiura, K ^a   Shibayama, T ^a   Gemba, K ^a   Segawa, Y ^b   Chikamori, K ^c   Yonei, T ^d   Hiraki, S ^e   Harada, M ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^c OKAYAMA ROSAI HOSPITAL   (Japan)

^d National Hospital Organization   (Japan)

^e Japanese Red Cross Okayama Hospital   (Japan)

Author keywords

Cisplatin; Irinotecan; Non small cell lung cancer; Phase I study; Small cell lung cancer

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBINS; HUMANS; LEUKOCYTE COUNT; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATELET COUNT;

EID: 0033063624     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690157     Document Type: Article

References (19)

1. Aoe K, Kiura K, Ueoka H, Tabata M, Chikamori K, Kohara H and Harada M (1997) Down-regulation of topoisomerase I induced by cisplatin. Proc Am Assoc Cancer Res 38: 15
2. Bonomi P (1996) Non-small cell lung cancer chemotherapy. In Lung Cancer - Principles and Practice. Pass HI, Mitchell JB, Johnson DH and Turrisi AT (eds), pp. 811-835. Lippincott-Raven: Philadelphia
3. Fujiwara Y, Yamakido M, Fukuoka M, Kudoh S, Furuse K, Ikegami H and Ariyoshi Y for the West Japan Lung Cancer Study Group (1994) Phase II study of irnotecan (CPT-11) and cisplatin (CDDP) in patients with small cell lung cancer (SCLC). Am Soc Clin Oncol 13: 335
4. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S and Taguchi T for the CPT-11 Lung Cancer Study Group (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16-20
5. Gandara DR, Wold E, Perez EA, Deisseroth AB, Doroshow J, Meyers F, McWhirter K, Hannigan J and DeGregorio MW (1989) Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Insts 81: 790-794
6. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM, Braun TJ, Natale RB and Balcerzak SP (1993) Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 11: 873-878
7. Gralla RJ, Casper ES, Kelsen DP, Braun DW, Dukeman ME, Martini N, Young CW and Golbey RB (1981) Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Int Med 95: 414-420
8. Hsiang Y-H and Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722-1726
9. Kaneda N, Nagata H, Furuta T and Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715-1720
10. Kudoh S, Takada M, Masuda N, Nakagawa K, Itoh K, Kususnoki Y, Negoro S, Matsui K, Takifuji N, Morino H and Fukuoka M (1993) Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung cancer xenografts. Jpn J Cancer Res 84: 203-207
11. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji S, Negoro S, Nishioka M, Nakagawa K and Takada M (1992a) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225-1229
12. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K und Kishimoto S (1992b) CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10: 1775-1780
13. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Takifuji N, Nakagawa K, Tamanoi M, Nitta T, Hirashima T, Negoro S and Takada M (1993) Phase I and pharmacological study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68: 777-782
14. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, Hirashima T, Tamanoi M, Nitta T, Yano T, Negoro S, Takifuji N and Takada M (1994) Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 12: 90-96
15. Nakagawa K, Fukuoka M, Niitani H and the CPT-11 Lung Cancer Study Group (1993) Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC). Am Soc Clin Oncol 12: 332
16. Ohnoshi T, Hiraki S, Ueoka H, Kiura K, Kamei H, Horiguchi T, Kodani T, Maeda T, Tabata M, Shibayama T, Segawa Y, Miyatake K, Takigawa N and Kimura I (1993) Pilot study of cyclophosphamide-doxorubicin-vineristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer. Cancer 72: 1597-1601
17. Oken MM, Davis TE, Greech RH, McFadden ET, Tormey DC, Carbone PP and Horton J (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655
18. Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen T-L, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA and Donehower RC (1996) Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 14: 3074-3084
19. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T and Tsuru D (1991) CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 14: 341-349